Henlius Reports Sustained Growth in Revenues and Profits for 2025 In 2025, Henlius announced impressive financial results, marking its third consecutive year of profitability, growing income and profits significantly.

Henlius Reports Sustained Growth in Revenues and Profits for 2025 #China #Shanghai #Henlius #Hanquyou #Serplulimab

Henlius Reports Strong Growth and Market Expansion in 2025 Financial Results Henlius showcases remarkable financial growth in 2025, marking the third consecutive profitable year, with significant success in global market penetration and innovation.

Henlius Reports Strong Growth and Market Expansion in 2025 Financial Results #China #Shanghai #Henlius #Hanquyou #Serplulimab

Henlius Achieves Major Milestone with First Shipment of Hanquyou Biosimilar to the U.S. Henlius has marked a significant milestone by shipping its first biosimilar, Hanquyou, to the U.S., expanding its global reach in biotechnology.

Henlius Achieves Major Milestone with First Shipment of Hanquyou Biosimilar to the U.S. #China #Shanghai #Henlius #Hanquyou #HERCESSI™